Literature DB >> 26996110

Expression Levels of Proinflammatory Cytokines and NLRP3 Inflammasome in an Experimental Model of Oxazolone-induced Colitis.

Aleksandr Zherebiatiev1, Aleksandr Kamyshnyi2.   

Abstract

IL-1β and IL-17A are two cytokines with strong proinflammatory activities and are now known to be involved in a number of chronic inflammatory disorders. High-mobility group box 1 (HMGB1) is a nuclear protein regulating the expression of these proinflammatory cytokines. The NLRP3 inflammasome promotes the maturation of the IL-1β and its activation has been shown as a critical mechanism in the pathogenesis of inflammatory bowel disease (IBD). However, underlying mechanisms to modulate their production in IBD are still unclear. The aim of this study was to investigate the expression levels of mRNA for the NLRP3 inflammasome, HMGB1 and proinflammatory cytokines, IL-1β, IL-17A in the inflamed colon of rats with experimental oxazolone-induced colitis. Experiments were carried out on male wistar rats. IL-1β, IL-17A, HMGB1 and NLRP3 inflammasome mRNA expression were analyzed by real-time reverse transcriptase-polymerase chain reaction. Our results indicated that the expression levels of IL-1β, IL-17A, NLRP3 and HMGB1 were elevated in the inflamed colon of rats with oxazolone-induced colitis.

Entities:  

Keywords:  Colitis; High mobility group box 1 protein; IL-17A; IL-1β; Inflammasome; NLR family

Mesh:

Substances:

Year:  2016        PMID: 26996110

Source DB:  PubMed          Journal:  Iran J Allergy Asthma Immunol        ISSN: 1735-1502            Impact factor:   1.464


  2 in total

1.  The Severity of Oxidative Stress in Comorbid Chronic Obstructive Pulmonary Disease (COPD) and Hypertension: Does it Depend On ACE and AGT Gene Polymorphisms?

Authors:  Mariya Marushchak; Khrystyna Maksiv; Inna Krynytska; Olha Dutchak; Nina Behosh
Journal:  J Med Life       Date:  2019 Oct-Dec

Review 2.  Roles of the inflammasome in the gut‑liver axis (Review).

Authors:  Junfeng Wang; Rui Dong; Shan Zheng
Journal:  Mol Med Rep       Date:  2018-11-20       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.